PMID- 35984843
OWN - NLM
STAT- MEDLINE
DCOM- 20220823
LR  - 20220830
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 17
IP  - 8
DP  - 2022
TI  - Management of de novo metastatic hormone-sensitive prostate cancer: A 
      comprehensive report of a single-center experience.
PG  - e0264800
LID - 10.1371/journal.pone.0264800 [doi]
LID - e0264800
AB  - BACKGROUND: Upfront docetaxel or novel hormonal agents (NHA) such as abiraterone 
      and enzalutamide have become the standard of care for metastatic hormone 
      sensitive prostate cancer (mHSPC). We evaluated real-world management of patients 
      treated with these agents at a single center. PATIENTS AND METHODS: Patients with 
      de novo mHSPC treated with upfront docetaxel or an NHA between January 2014 and 
      April 2019 at Mount Sinai Health System were included. We evaluated time to next 
      treatment (TTNT), PSA progression free survival (PFS) and overall survival (OS) 
      after initial treatment with these drugs. Kaplan Meier method and multivariable 
      Cox proportional hazards models were used for analysis. We additionally assessed 
      the prognostic value of post-treatment PSA. RESULTS: We identified 94 de novo 
      mHSPC patients; 52 and 42 treated with upfront docetaxel and NHAs, respectively. 
      NHAs were associated with a median TTNT of 20.7 months compared to 10.1 months 
      with docetaxel (log-rank p = 0.023). We also observed median PSA PFS of 19 months 
      for NHAs and 13.2 months for docetaxel (p = 0.069). However, OS between the two 
      treatment groups was unchanged. Among docetaxel treated patients, TTNT was 
      shorter among those with high metastasis burden (9.63 vs 25.5 months, p = 0.026) 
      which was not observed among NHA treated patients (25.1 vs 20.7 months, p = 
      0.79). Regardless of treatment, lower post-treatment PSA levels were associated 
      with improved TTNT (58.95 vs. 11.57 vs. 9.4 months for PSA </=0.2, 0.2-0.4, 
      >0.4ng/ml, respectively; p<0.001). CONCLUSION: Real world data demonstrated a 
      shorter duration of treatment with docetaxel than NHAs, reflecting the 
      time-limited nature of docetaxel regimens compared to the treat-till-progression 
      approach of NHAs. While TTNT was generally longer for NHAs than docetaxel, some 
      docetaxel-treated patients achieved significant periods of time off treatment. In 
      addition, the depth of PSA response following combination treatment may hold 
      prognostic value for mHSPC outcomes.
FAU - Guin, Sunny
AU  - Guin S
AD  - Sema4, Stamford, CT, United States of America.
FAU - Liaw, Bobby K
AU  - Liaw BK
AD  - Mount Sinai Health System, New York, NY, United States of America.
FAU - Jun, Tomi
AU  - Jun T
AD  - Mount Sinai Health System, New York, NY, United States of America.
FAU - Ayers, Kristin
AU  - Ayers K
AD  - Sema4, Stamford, CT, United States of America.
FAU - Patel, Bonny
AU  - Patel B
AD  - Sema4, Stamford, CT, United States of America.
FAU - O'Connell, Timmy
AU  - O'Connell T
AD  - Sema4, Stamford, CT, United States of America.
FAU - Deitz, Matthew
AU  - Deitz M
AD  - Sema4, Stamford, CT, United States of America.
FAU - Klein, Michael
AU  - Klein M
AD  - Sema4, Stamford, CT, United States of America.
FAU - Mullaney, Tommy
AU  - Mullaney T
AD  - Sema4, Stamford, CT, United States of America.
FAU - Prentice, Tony
AU  - Prentice T
AD  - Sema4, Stamford, CT, United States of America.
FAU - Newman, Scott
AU  - Newman S
AD  - Sema4, Stamford, CT, United States of America.
FAU - Fink, Marc
AU  - Fink M
AD  - Sema4, Stamford, CT, United States of America.
FAU - Zhou, Xiang
AU  - Zhou X
AD  - Sema4, Stamford, CT, United States of America.
FAU - Schadt, Eric E
AU  - Schadt EE
AD  - Sema4, Stamford, CT, United States of America.
AD  - Mount Sinai Health System, New York, NY, United States of America.
FAU - Chen, Rong
AU  - Chen R
AD  - Sema4, Stamford, CT, United States of America.
AD  - Mount Sinai Health System, New York, NY, United States of America.
FAU - Oh, William K
AU  - Oh WK
AUID- ORCID: 0000-0001-5113-8147
AD  - Sema4, Stamford, CT, United States of America.
AD  - Mount Sinai Health System, New York, NY, United States of America.
LA  - eng
PT  - Journal Article
DEP - 20220819
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Hormones)
RN  - 15H5577CQD (Docetaxel)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - *Antineoplastic Agents/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols
MH  - Docetaxel/therapeutic use
MH  - Hormones/therapeutic use
MH  - Humans
MH  - Male
MH  - Prostate-Specific Antigen/therapeutic use
MH  - *Prostatic Neoplasms, Castration-Resistant/pathology
MH  - Retrospective Studies
MH  - Treatment Outcome
PMC - PMC9390935
COIS- The authors have declared that no competing interests exist.
EDAT- 2022/08/20 06:00
MHDA- 2022/08/24 06:00
PMCR- 2022/08/19
CRDT- 2022/08/19 13:42
PHST- 2022/02/15 00:00 [received]
PHST- 2022/08/03 00:00 [accepted]
PHST- 2022/08/19 13:42 [entrez]
PHST- 2022/08/20 06:00 [pubmed]
PHST- 2022/08/24 06:00 [medline]
PHST- 2022/08/19 00:00 [pmc-release]
AID - PONE-D-22-04683 [pii]
AID - 10.1371/journal.pone.0264800 [doi]
PST - epublish
SO  - PLoS One. 2022 Aug 19;17(8):e0264800. doi: 10.1371/journal.pone.0264800. 
      eCollection 2022.